Menu
close
Please contact us for more information or to learn if you are eligible to participate.
To investigate the efficacy of the oral FXIa inhibitor asundexian in prevention of ischemic stroke and its safety (bleeding) compared with placebo on top of background antiplatelet therapy in adult participants after an acute non-cardioembolic ischemic stroke or high-risk TIA
Principal Investigator | Gloria Simms, M.D. |
Co-PI | Esmeralda Cordoso-Mendoza |
Sponsor | Bayer AG |
Type of Trial | Interventional |